NO20070996L - Fremgangsmate for behandling av CCR2 medierte sykdommer eller lidelser - Google Patents
Fremgangsmate for behandling av CCR2 medierte sykdommer eller lidelserInfo
- Publication number
- NO20070996L NO20070996L NO20070996A NO20070996A NO20070996L NO 20070996 L NO20070996 L NO 20070996L NO 20070996 A NO20070996 A NO 20070996A NO 20070996 A NO20070996 A NO 20070996A NO 20070996 L NO20070996 L NO 20070996L
- Authority
- NO
- Norway
- Prior art keywords
- methods
- treating
- patients
- disorders
- therapeutic
- Prior art date
Links
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 title abstract 3
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 208000035475 disorder Diseases 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 3
- 229940124597 therapeutic agent Drugs 0.000 abstract 3
- 241001465754 Metazoa Species 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 241000283690 Bos taurus Species 0.000 abstract 1
- 241000287828 Gallus gallus Species 0.000 abstract 1
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 241000282898 Sus scrofa Species 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 210000000577 adipose tissue Anatomy 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 235000020997 lean meat Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59268304P | 2004-07-30 | 2004-07-30 | |
| PCT/IB2005/002162 WO2006013427A2 (en) | 2004-07-30 | 2005-07-18 | Treatment of ccr2 mediated diseases or disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20070996L true NO20070996L (no) | 2007-04-23 |
Family
ID=35207829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20070996A NO20070996L (no) | 2004-07-30 | 2007-02-21 | Fremgangsmate for behandling av CCR2 medierte sykdommer eller lidelser |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20090196823A1 (enExample) |
| EP (1) | EP1778285A2 (enExample) |
| JP (1) | JP2008508253A (enExample) |
| KR (1) | KR20080044360A (enExample) |
| CN (1) | CN101005855A (enExample) |
| AU (1) | AU2005268545A1 (enExample) |
| BR (1) | BRPI0513953A (enExample) |
| CA (1) | CA2575612A1 (enExample) |
| IL (1) | IL180675A0 (enExample) |
| MX (1) | MX2007001204A (enExample) |
| NO (1) | NO20070996L (enExample) |
| RU (1) | RU2007103332A (enExample) |
| WO (1) | WO2006013427A2 (enExample) |
| ZA (1) | ZA200700823B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7629351B2 (en) | 2006-07-28 | 2009-12-08 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process |
| US7671062B2 (en) | 2006-07-28 | 2010-03-02 | Bristol-Myers Squibb Company | Modulators of chemokine receptor activity, crystalline forms and process |
| US7687508B2 (en) | 2006-07-28 | 2010-03-30 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| PE20110774A1 (es) | 2008-08-18 | 2011-10-13 | Amgen Fremont Inc | Anticuerpos para ccr2 |
| US8383812B2 (en) | 2009-10-13 | 2013-02-26 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes |
| US9726666B2 (en) | 2011-06-13 | 2017-08-08 | Tla Targeted Immunotherapies Ab | Diagnosing and treating inflammatory diseases |
| DK2723360T3 (en) * | 2011-06-27 | 2017-08-28 | Univ Pierre Et Marie Curie Paris 6 | CCR2 antagonist peptides |
| WO2022235440A1 (en) * | 2021-04-21 | 2022-11-10 | The United States Government As Represented By The Department Of Veterans Affairs | Method for treating traumatic brain injury, spinal cord injury, or stroke using small molecule inhibitors of ccr2 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6312689B1 (en) * | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
| FR2792837B1 (fr) * | 1999-04-29 | 2001-07-13 | Centre Nat Rech Scient | Medicaments utiles pour le traitement des troubles de la regulation de la masse adipeuse et des maladies associees aux troubles de la production de leptine |
| US20050245537A1 (en) * | 2002-04-24 | 2005-11-03 | Noboru Tsuchimori | Use of compounds having ccr antagonism |
| JP2007523871A (ja) * | 2003-07-15 | 2007-08-23 | メルク エンド カムパニー インコーポレーテッド | ケモカイン受容体活性の７および８員複素環式シクロペンチルベンジルアミドモジュレーター |
| MXPA06007000A (es) * | 2003-12-18 | 2006-08-31 | Incyte Corp | Derivados de 3-cicloalquilaminopirrolidina como moduladores de receptores de quimiocina. |
-
2005
- 2005-07-18 CA CA002575612A patent/CA2575612A1/en not_active Abandoned
- 2005-07-18 BR BRPI0513953-8A patent/BRPI0513953A/pt not_active IP Right Cessation
- 2005-07-18 MX MX2007001204A patent/MX2007001204A/es unknown
- 2005-07-18 WO PCT/IB2005/002162 patent/WO2006013427A2/en not_active Ceased
- 2005-07-18 KR KR1020087010937A patent/KR20080044360A/ko not_active Ceased
- 2005-07-18 EP EP05777347A patent/EP1778285A2/en not_active Withdrawn
- 2005-07-18 RU RU2007103332/14A patent/RU2007103332A/ru not_active Application Discontinuation
- 2005-07-18 AU AU2005268545A patent/AU2005268545A1/en not_active Abandoned
- 2005-07-18 CN CNA2005800276608A patent/CN101005855A/zh active Pending
- 2005-07-18 JP JP2007523167A patent/JP2008508253A/ja not_active Withdrawn
- 2005-09-16 US US11/658,989 patent/US20090196823A1/en not_active Abandoned
-
2007
- 2007-01-11 IL IL180675A patent/IL180675A0/en unknown
- 2007-01-29 ZA ZA200700823A patent/ZA200700823B/xx unknown
- 2007-02-21 NO NO20070996A patent/NO20070996L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006013427A2 (en) | 2006-02-09 |
| WO2006013427A3 (en) | 2006-06-08 |
| CA2575612A1 (en) | 2006-02-09 |
| RU2007103332A (ru) | 2008-08-10 |
| KR20080044360A (ko) | 2008-05-20 |
| MX2007001204A (es) | 2007-03-23 |
| US20090196823A1 (en) | 2009-08-06 |
| AU2005268545A1 (en) | 2006-02-09 |
| IL180675A0 (en) | 2007-06-03 |
| ZA200700823B (en) | 2008-10-29 |
| CN101005855A (zh) | 2007-07-25 |
| EP1778285A2 (en) | 2007-05-02 |
| JP2008508253A (ja) | 2008-03-21 |
| BRPI0513953A (pt) | 2008-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20070996L (no) | Fremgangsmate for behandling av CCR2 medierte sykdommer eller lidelser | |
| TW200612957A (en) | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions | |
| UA102669C2 (xx) | Застосування інгібіторів dpp iv$применение ингибиторов dpp iv | |
| NO20074999L (no) | Metode og preparat for behandling av perifere vaskulaere sykdommer | |
| EA200900177A1 (ru) | Замещенные ациланилиды и способы их применения | |
| MX2010004074A (es) | Combinacion 059. | |
| ATE432693T1 (de) | Kombinationstherapie zur behandlung von diabetes und dadurch bedingten leiden sowie zur behandlung von mittels erhöhung des glp-1-spiegels im blut verbesserten leiden | |
| WO2007089617A3 (en) | Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith | |
| BRPI0518565A2 (pt) | composiÇÕes cardiovasculares | |
| DE602005013811D1 (de) | Behandlung von fettsucht und verbundenen erkrankungen | |
| EA201001695A1 (ru) | Применение эпотилона d для лечения заболеваний, связанных с тау-белком | |
| MX2009003658A (es) | Compuestos heterociclicos que contienen nitrogeno biciclico para utilizarse como inhibidores de desaturasa de estearoilo-coa. | |
| NO20082448L (no) | Kombinasjoner av angiopoietin-2 antagonister og VEGF-A, KDR og/eller FLT1 antagonist for behandling av cancer | |
| EP2361934A3 (en) | Hepatocyte growth factor (HGF) binding proteins | |
| NO20076241L (no) | Terapier for vaskulaere sykdommer | |
| EA200601414A1 (ru) | Способ контроля потребления пищи | |
| NO20076405L (no) | Anvendelse av 24-nor-UDCA | |
| BRPI0712561B8 (pt) | Uso de 3-oxo-3,4-diidro-2-pirazinacarboxamida | |
| EA201000630A1 (ru) | Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов в крови | |
| MA29397B1 (fr) | Methode de traitement ou de prevention du diabete de type 2 | |
| WO2006114105A3 (en) | Use of modified factor vii for treating bleeding | |
| Nayak et al. | Influence of physical activity of the rescuer on chest compression duration and its effects on hemodynamics and fatigue levels of the rescuer: a simulation-based study | |
| MXPA06012143A (es) | Arilsulfonamidas y usos relacionados con las mismas. | |
| DE602008004556D1 (de) | Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin | |
| TW200738255A (en) | Methods of regulating renalase (Monoamine Oxidase C) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |